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The appropriate treatment strategy for prostate cancer is critically 
dependent on its accurate staging (1). Current screening techniques (CT, 
MRI, Ultrasound) fail to reliably distinguish clinically-localized disease 
from metastatic disease. A reliable noninvasive method for detection of 
prostate cancer metastases would thus be of immense clinical benefit for a) 
disease staging b) implementing the appropriate treatment strategy c) 
monitoring the effects of therapy. To address this need, many research 
groups have focused on the development of radiolabeled androgen receptor 
(AR) ligands for prostate cancer imaging, based on the observation that 
most prostate tumors and metastases express AR (2,3). The majority of 
these studies to date have focused on steroid-based ligands (2,4,5). 
The antiandrogens RU 59063 and RU 58841 (Table l), are 
prototypes of a new series of nonsteroidal androgen receptor ligands that 
display high AR affinity and selectivity (6,7). The ease of synthesis and 
structural modification of these compounds as compared to steroid-based 
AR ligands, prompted us to select them as leads for development of a 
SPECT AR radioligand. We have previously shown that substitution of the 
trifluoromethyl group of RU 59063 with iodine leads to an improvement in 
AR binding affinity (8). Accordingly, a series of iodinated analogs of RU 
59063 and RU 58841 was synthesized for investigation as in vivo AR 
radioligands (Table 1). 
Compounds 1-4 were synthesized from 4-cyano-3-iodoaniline using 
previously reported methods (8). Radioiodination of compounds 1-4 with 
iodine-125 were achieved in 50-65% radiochemical yield by an ammonium 
sulfate catalyzed solid phase exchange procedure (Scheme 1). Radiolabeled 
products were purified either by elution through an anion exchange resin or 
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Table 1. Inhibition Constants (Ki) for Ligands at the Rat AR 
Scheme 1 
R X 
R I X 
x=o,s 
R = CH3, (CH2)4OH 
x=o, s 
R = CH3, (CHJ40H 
Scheme 2 a 
R = CH3, (CH340H R = CH3. (CHA40H 
a Reagents: (a) Sn2(Bu)G, (Ph,P),Pd, toluene, reflux; (b) 3% aq. H202, Na12% 
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a silica gel Sep Pak. The chemical purity and specific activity of the 
radioiodinated ligands were >95% and >155 Ci/mrnole, respectively. In 
addition, the hydantoin derivatives ['251]2 and ['251]4 were obtained in 76- 
85% radiochemical yield by a no-carrier-added radioiododestannylation 
procedure from their corresponding tri-n-butylstannyl derivatives (Scheme 
In conclusion, a series of ['2SI]-labeled nonsteroidal AR radioligands 
has been synthesized using either carrier-added or no-carrier-added 
methods. Biological studies are underway to evaluate their utility as in vivo 
radioligands for AR imaging. 
2). 
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